Generic azacitidine tablet tested against Brand-Name onureg in AML patients
NCT ID NCT06326697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared a generic azacitidine tablet to the brand-name drug Onureg in 32 adults with acute myeloid leukemia (AML) who are in remission. Participants took a single dose of each drug under fasting conditions to see if the generic version is absorbed similarly. The goal is to show the generic is equivalent, which could offer a more affordable treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine (chemotherapy drug)
What this could lead to
If successful, this could provide a more affordable generic version of azacitidine for AML patients in remission.
What could go wrong
This is a small, early-phase bioequivalence study, not a test of effectiveness. It only checks how the drug is absorbed in the body, not whether it improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia